BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10428384)

  • 1. Benzofuran based PDE4 inhibitors.
    McGarry DG; Regan JR; Volz FA; Hulme C; Moriarty KJ; Djuric SW; Souness JE; Miller BE; Travis JJ; Sweeney DM
    Bioorg Med Chem; 1999 Jun; 7(6):1131-9. PubMed ID: 10428384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma.
    Buckley G; Cooper N; Dyke HJ; Galleway F; Gowers L; Gregory JC; Hannah DR; Haughan AF; Hellewell PG; Kendall HJ; Lowe C; Maxey R; Montana JG; Naylor R; Picken CL; Runcie KA; Sabin V; Tuladhar BR; Warneck JB
    Bioorg Med Chem Lett; 2000 Sep; 10(18):2137-40. PubMed ID: 10999488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First dual M3 antagonists-PDE4 inhibitors: synthesis and SAR of 4,6-diaminopyrimidine derivatives.
    Provins L; Christophe B; Danhaive P; Dulieu J; Durieu V; Gillard M; Lebon F; Lengelé S; Quéré L; van Keulen B
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1834-9. PubMed ID: 16439121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orally active indole N-oxide PDE4 inhibitors.
    Hulme C; Mathew R; Moriarty K; Miller B; Ramanjulu M; Cox P; Souness J; Page KM; Uhl J; Travis J; Labaudiniere R; Huang F; Djuric SW
    Bioorg Med Chem Lett; 1998 Nov; 8(21):3053-8. PubMed ID: 9873675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents.
    Van der Mey M; Bommelé KM; Boss H; Hatzelmann A; Van Slingerland M; Sterk GJ; Timmerman H
    J Med Chem; 2003 May; 46(10):2008-16. PubMed ID: 12723963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substituted furans as inhibitors of the PDE4 enzyme.
    Perrier H; Bayly C; Laliberté F; Huang Z; Rasori R; Robichaud A; Girard Y; Macdonald D
    Bioorg Med Chem Lett; 1999 Feb; 9(3):323-6. PubMed ID: 10091677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual M3 antagonists-PDE4 inhibitors. Part 2: Synthesis and SAR of 3-substituted azetidinyl derivatives.
    Provins L; Christophe B; Danhaive P; Dulieu J; Gillard M; Quéré L; Stebbins K
    Bioorg Med Chem Lett; 2007 Jun; 17(11):3077-80. PubMed ID: 17398090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel selective PDE4 inhibitors. 1. Synthesis, structure-activity relationships, and molecular modeling of 4-(3,4-dimethoxyphenyl)-2H-phthalazin-1-ones and analogues.
    Van der Mey M; Hatzelmann A; Van der Laan IJ; Sterk GJ; Thibaut U; Timmerman H
    J Med Chem; 2001 Aug; 44(16):2511-22. PubMed ID: 11472205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2,1,3-Benzothiadiazine derivatives: synthesis and screening versus PDE4 enzyme.
    Tait A; Luppi A; Avallone R; Baraldi M
    Farmaco; 2005 Aug; 60(8):653-63. PubMed ID: 15963514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The synthesis and biological evaluation of a novel series of indole PDE4 inhibitors I.
    Hulme C; Moriarty K; Miller B; Mathew R; Ramanjulu M; Cox P; Souness J; Page KM; Uhl J; Travis J; Huang FC; Labaudiniere R; Djuric SW
    Bioorg Med Chem Lett; 1998 Jul; 8(14):1867-72. PubMed ID: 9873449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel selective phosphodiesterase (PDE4) inhibitors. 4. Resolution, absolute configuration, and PDE4 inhibitory activity of cis-tetra- and cis-hexahydrophthalazinones.
    Van der Mey M; Boss H; Couwenberg D; Hatzelmann A; Sterk GJ; Goubitz K; Schenk H; Timmerman H
    J Med Chem; 2002 Jun; 45(12):2526-33. PubMed ID: 12036361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of imidazol-2-one and 2-cyanoiminoimidazole derivatives: novel series of PDE4 inhibitors.
    Andrés JI; Alonso JM; Díaz A; Fernández J; Iturrino L; Martínez P; Matesanz E; Freyne EJ; Deroose F; Boeckx G; Petit D; Diels G; Megens A; Somers M; Van Wauwe J; Stoppie P; Cools M; De Clerck F; Peeters D; de Chaffoy D
    Bioorg Med Chem Lett; 2002 Feb; 12(4):653-8. PubMed ID: 11844693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives.
    Napoletano M; Norcini G; Pellacini F; Marchini F; Morazzoni G; Ferlenga P; Pradella L
    Bioorg Med Chem Lett; 2001 Jan; 11(1):33-7. PubMed ID: 11140727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and structure-activity relationships of guanine analogues as phosphodiesterase 7 (PDE7) inhibitors.
    Barnes MJ; Cooper N; Davenport RJ; Dyke HJ; Galleway FP; Galvin FC; Gowers L; Haughan AF; Lowe C; Meissner JW; Montana JG; Morgan T; Picken CL; Watson RJ
    Bioorg Med Chem Lett; 2001 Apr; 11(8):1081-3. PubMed ID: 11327595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 8-Methoxyquinoline-5-carboxamides as PDE4 inhibitors: a potential treatment for asthma.
    Buckley GM; Cooper N; Dyke HJ; Galleway FP; Gowers L; Haughan AF; Kendall HJ; Lowe C; Maxey R; Montana JG; Naylor R; Oxford J; Peake JC; Picken CL; Runcie KA; Sabin V; Sharpe A; Warneck JB
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1613-5. PubMed ID: 12039574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclic AMP phosphodiesterase 4 isoenzyme inhibitory activity of (R)- and (S)-isomer of 7-methyl- or 8-alkyl-4,5,7,8-tetrahydroimidazo[2,1-i]- purin-5-one.
    Suzuki H; Nomura M; Miyamoto K; Sawanishi H; Yamamoto K
    Biol Pharm Bull; 2004 Mar; 27(3):357-60. PubMed ID: 14993802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-Substituted-4-methoxybenzimidazole-based PDE4 inhibitors.
    Regan J; Bruno J; McGarry D; Poli G; Hanney B; Bower S; Travis J; Sweeney D; Miller B; Souness J; Djuric S
    Bioorg Med Chem Lett; 1998 Oct; 8(19):2737-42. PubMed ID: 9873613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
    Macdonald D; Mastracchio A; Perrier H; Dubé D; Gallant M; Lacombe P; Deschênes D; Roy B; Scheigetz J; Bateman K; Li C; Trimble LA; Day S; Chauret N; Nicoll-Griffith DA; Silva JM; Huang Z; Laliberté F; Liu S; Ethier D; Pon D; Muise E; Boulet L; Chan CC; Styhler A; Charleson S; Mancini J; Masson P; Claveau D; Nicholson D; Turner M; Young RN; Girard Y
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5241-6. PubMed ID: 16168647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
    Kleinman EF; Campbell E; Giordano LA; Cohan VL; Jenkinson TH; Cheng JB; Shirley JT; Pettipher ER; Salter ED; Hibbs TA; DiCapua FM; Bordner J
    J Med Chem; 1998 Jan; 41(3):266-70. PubMed ID: 9464356
    [No Abstract]   [Full Text] [Related]  

  • 20. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.
    Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Royer F; Wrigglesworth R; Schellhaas J; Barvian M; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Berna P; Soulard P
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4607-13. PubMed ID: 15324874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.